Updated on 17 October 2014
Covance has recieved 2014 Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award
Singapore: Covance, a global drug development company, has recieved the 2014 Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award, for its business performance and continued investments in the Asia Pacific region. The award was presented to Covance at the Frost & Sullivan Asia Pacific Best Practice Awards ceremony in Singapore.
Covance has expanded its central laboratory and nutritional chemistry laboratory facilities in Singapore, added to its preclinical and clinical footprint in China, and has marked growth in clinical operations in China, Japan, Korea and other Asia Pacific countries.
"To meet present and future drug development requirements, and to tap the fast growing opportunities in Asia Pacific region, Covance expanded its investments in its clinical and preclinical business areas. Covance has shown strong growth and has emerged as a leader in the rapidly growing Asia Pacific CRO market. With its strong overall performance, Covance has earned Frost & Sullivan's 2014 Growth Excellence Leadership Award," said Mr Sanjeev Kumar, Consultant, Healthcare Practice Asia Pacific, Frost & Sullivan.
"This award further validates the significance of our investments in our late-stage and early development service lines in the Asia Pacific region and acknowledges our leadership position in the CRO industry" said Mr Nick Wright, vice president and general manager, phase II-IV clinical development Asia Pacific, at Covance. "Covance is the only CRO in the region with the expertise to develop a molecule from discovery through all preclinical and clinical milestone and we're very committed to continue bringing our Asia Pacific clients solutions that advance drug development."